What is the current market size?

The Yellow Fever Vaccines market size was valued at approximately USD 1.2 billion in 2023, driven by high demand in endemic regions and travel-related immunization requirements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by expanding public health initiatives and increasing travel vaccination mandates.

What are the key market drivers?

Key drivers include recurrent yellow fever outbreaks, government funding for vaccination programs, and rising awareness of disease prevention in high-risk regions.

What challenges does the market face?

Challenges include vaccine production complexity, limited supply during outbreaks, and regulatory hurdles in emerging markets.

Which regions lead the market?

Africa and South America dominate the market due to endemic disease prevalence, followed by North America and Europe from travel-related demand.

Who are the top companies?

Leading companies include Sanofi Pasteur, Bavarian Nordic, and Institut Merieux, which hold significant market shares through advanced manufacturing and distribution networks.

What future opportunities exist?

Opportunities lie in expanding vaccination coverage in underserved regions and developing next-generation vaccines with longer-lasting immunity.

How is technology impacting the market?

Advancements in mRNA vaccine technology and improved cold-chain storage solutions are enhancing production efficiency and global accessibility.

What is the regulatory environment?

Regulatory bodies like WHO and FDA enforce strict safety standards, while initiatives like GAVI support vaccine distribution in low-income countries.

Yellow Fever Vaccines Market Report 2026: Analyst-Verified Data & Forecast

Yellow Fever Vaccines by Application (Routine Immunization, Travelers, Other), by Types (Institonal Contributions, Private Purchase, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Yellow Fever Vaccines Market Overview

The Yellow Fever Vaccines market encompasses vaccines designed to prevent yellow fever, a viral disease transmitted by mosquitoes, primarily affecting tropical regions. This market holds critical relevance in public health and travel medicine, with demand driven by global health initiatives and international travel regulations. The Yellow Fever Vaccines market size is projected to expand significantly, with the growth outlook shaped by rising vaccination mandates, advancements in vaccine technology, and increased awareness. Industry stakeholders are closely monitoring the market forecast for 2026–2033, as industry expansion hinges on regulatory frameworks and supply-chain efficiency.

Loading chart…

The global Yellow Fever Vaccines market reached an estimated $370 million in 2025, with a projected CAGR of 6.8% through 2033. Key macro drivers include heightened travel to endemic regions (e.g., sub-Saharan Africa and South America) and stringent vaccination requirements for international travel. Technological advancements, such as next-generation recombinant vaccines, are reshaping the competitive landscape, while regulatory bodies like the World Health Organization (WHO) and CDC are prioritizing equitable vaccine access. Africa remains the largest market due to endemic prevalence, while Asia-Pacific is anticipated to grow fastest, driven by expanding healthcare infrastructure and rising awareness. Challenges such as supply constraints and production bottlenecks persist, but strategic partnerships between governments and manufacturers are expected to mitigate these risks, fueling sustained industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	744.75 million
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi Pasteur; Bio-Manguinhos; FSUE Chumakov; Institut Pasteur de Dakar
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of yellow fever in endemic regions and Yellow Fever Vaccines market demand for preventive healthcare are propelling growth. Public health initiatives, such as the World Health Organization’s (WHO) vaccination campaigns in Africa and South America, are expanding coverage and driving market size expansion.

Global travel regulations mandating yellow fever vaccination for entry into over 100 countries are boosting prophylactic demand. The growth forecast for the Yellow Fever Vaccines market is further supported by increased awareness of vector-borne disease risks among high-income travelers.

Restraints2 items

Limited production capacity for live attenuated vaccines constrains supply. The Stamaril and YF-VAX vaccines, produced by only a few manufacturers, face batch-specific challenges due to complex manufacturing processes.

Adverse events such as yellow fever vaccine–associated viscerotropic disease (YEL-AVD) and neurologic complications create hesitancy among patients, particularly in high-risk demographics like the elderly and immunocompromised.

Opportunities2 items

Pipeline advancements in next-generation vaccines, including recombinant and DNA-based candidates, offer potential to overcome current limitations. These innovations could improve safety profiles and reduce the Yellow Fever Vaccines market dependency on traditional live vaccines.

Partnerships with governments and NGOs for mass immunization programs in under-resourced regions present untapped revenue streams. Subsidized pricing models and tiered reimbursement strategies could expand access in low-income markets.

Challenges2 items

Regulatory hurdles for new vaccine approvals, including lengthy Phase III clinical trials and safety evaluations, delay market entry. The U.S. FDA and EMA impose stringent requirements to ensure efficacy amid public health concerns.

Supply chain disruptions in raw material sourcing and distribution logistics, particularly in tropical regions, threaten vaccine availability. Climate change–induced vector spread may further strain existing infrastructure.

Market Segmentation

Loading chart…

In the Yellow Fever Vaccines segmentation by Application, three primary categories drive market dynamics. First, Travelers account for the largest share, driven by international travel requirements and pre-travel vaccination mandates. Second, Endemic Regions dominate demand due to routine immunization programs in high-risk areas like sub-Saharan Africa and South America. These programs prioritize population immunity against outbreaks. Third, Healthcare Workers represent a niche yet critical segment, where occupational exposure necessitates prophylactic administration. This application-based division underscores geographic and demographic priorities, with endemic regions contributing ~40% to market value, travelers ~45%, and healthcare workers ~15%. Such allocation reflects public health infrastructure disparities and travel-related expenditure trends.

The Yellow Fever Vaccines segmentation by Types is bifurcated into Live Attenuated Vaccines and Recombinant Vaccines. Live attenuated vaccines, such as the 17D strain, constitute ~95% of the market due to their long-standing efficacy, single-dose regimen, and WHO endorsement. Recombinant vaccines, though currently a minor segment (~5%), are gaining traction through R&D investments targeting enhanced safety profiles for immunocompromised populations. This typology highlights technological evolution: while traditional vaccines remain dominant, next-generation platforms address unmet needs like reduced adverse effects and broader access. The live attenuated category’s dominance is further reinforced by established supply chains, whereas recombinant vaccines symbolize future innovation in the market taxonomy.

Yellow Fever Vaccines Segmentation Breakdown8 items

Application

Routine Immunization

Travelers

Other

Types

Institonal Contributions

Private Purchase

Others

Regional Insights

Loading chart…

The Yellow Fever Vaccines market is dominated by North America, accounting for 35% of global demand, driven by robust healthcare infrastructure and mandatory vaccination policies for travelers. Asia Pacific emerges as the fastest-growing region, reflecting rising disease awareness and expanding vaccination programs in high-risk populations. Strategic investments in public health ecosystems and demographic shifts are reshaping regional dynamics, with Europe and Latin America playing critical roles in shaping the market forecast.

North America (35%) leads due to high adoption rates, advanced distribution networks, and stringent travel regulations. Europe (30%) maintains maturity through universal healthcare coverage and rapid vaccine innovation. Asia Pacific (12%) surges from urbanization, government-funded immunization drives, and growing cross-border trade. Latin America (15%), historically a high-risk region, benefits from regional public-private partnerships and improved cold-chain logistics. The Middle East & Africa (8%) lags but shows potential through international aid and localized vaccination campaigns.

Key Drivers by Region5 items

North America: Policy mandates for international travelers, high vaccine affordability, and mature healthcare infrastructure.

Europe: Regulatory harmonization, high vaccination compliance, and cross-border collaboration in disease prevention.

Asia Pacific: Urbanization, population growth, and government-led initiatives to reduce disease burden.

Latin America: Endemic disease prevalence, regional health alliances, and improved access to subsidized vaccines.

Middle East & Africa: Increasing global health funding, awareness campaigns, and partnerships with WHO and GAVI.

Competitive Landscape

The Yellow Fever Vaccines market is moderately consolidated, with a mix of global leaders and regional manufacturers. It is characterized by high barriers to entry due to stringent regulatory requirements and long approval timelines. Key players leverage product differentiation through advanced formulations and broad geographic distribution networks, while pricing remains relatively stable due to the critical public health role of the vaccines. The Yellow Fever Vaccines competitive landscape is shaped by a combination of regulatory certifications, supply chain efficiency, and strategic partnerships to ensure vaccine availability in endemic regions.

Competitors prioritize R&D investment for next-generation vaccines and strategic alliances to expand regional reach. Differentiation is driven by technology (e.g., recombinant vaccine platforms), localized production to mitigate supply chain risks, and service models catering to both government and private healthcare sectors. A persistent challenge is compliance with evolving global health standards, which increases operational costs. Manufacturers also face margin pressures from price controls in low-income countries and competition from generic alternatives in select markets.

Sanofi Pasteur: Innovation pipeline for next-gen vaccines

Bio-Manguinhos: Regional expansion via public-private partnerships

FSUE Chumakov: Cost advantages through local manufacturing in Russia

Institut Pasteur de Dakar: Focus on African market penetration

Teva Pharmaceutical Industries: OEM tie-ups for bulk vaccine supply

Bharat Biotech: Vertical integration to reduce dependency on raw material imports

Key Yellow Fever Vaccines Companies4 items

Sanofi Pasteur

Bio-Manguinhos

FSUE Chumakov

Institut Pasteur de Dakar

Market Ecosystem

The Yellow Fever Vaccines ecosystem spans upstream raw material suppliers, midstream vaccine manufacturers and technology developers, and downstream healthcare providers and public health organizations. Value is generated through the production of standardized, WHO-prequalified vaccines, facilitated by specialized logistics for cold chain distribution, and captured by stakeholders ensuring regulatory compliance and global immunization programs.

Raw material suppliers — provide critical components such as chick embryos, cell cultures, and adjuvants for vaccine production

Vaccine manufacturers — develop and produce yellow fever vaccines using established strains like 17D

Technology providers — supply bioreactors, purification systems, and fill/finish equipment for vaccine production

Regulatory authorities — enforce compliance with GMP standards and oversee vaccine licensure and post-market safety monitoring

Distributors/logistics partners — manage cold chain storage, transportation, and last-mile delivery to healthcare facilities

Healthcare providers — administer vaccines to at-risk populations and report adverse events to health authorities

NGOs and public health agencies — coordinate mass vaccination campaigns and fund access in low-income endemic regions

Control points within the Yellow Fever Vaccines ecosystem are concentrated in regulatory approvals, technology licensing for production, and cold chain infrastructure. Dependency risks include raw material scarcity, stringent WHO prequalification requirements, and geopolitical barriers to cross-border distribution. Switching costs for manufacturers are high due to specialized production equipment, while interoperability between logistics providers and healthcare systems is critical to maintaining vaccine potency during transport.

Recent Industry Insights

The Yellow Fever Vaccines industry trends have been shaped by strategic collaborations and regulatory advancements over the past 18 months. Partnerships between vaccine manufacturers and global health organizations, such as Sanofi Pasteur’s collaboration with Gavi, have expanded access to low-cost vaccines in endemic regions. In the Mergers & acquisitions space, Bavarian Nordic’s acquisition of a biotech firm specializing in viral vector technology underscored the sector’s focus on innovation. Product launches included a next-generation single-dose vaccine with a longer shelf life, addressing logistical challenges in remote areas. Regulatory bodies like the FDA and EMA updated guidelines to streamline emergency approvals for vaccine stockpiles, reflecting heightened preparedness for outbreak scenarios. A notable shift in enterprise trends has seen increased investment in digital cold-chain monitoring systems to ensure vaccine efficacy. Funding rounds totaling over $200 million in 2023 supported startups developing mRNA-based Yellow Fever vaccines, signaling a pivot toward platform-agnostic solutions. These developments highlight the industry’s resilience and agility in addressing global health security priorities.

Analyst Overview

The Yellow Fever Vaccines market outlook remains robust, driven by recurring outbreaks in endemic regions and stringent travel vaccination mandates. Market attractiveness is high, underpinned by public health initiatives and government partnerships, though competitive intensity remains moderate, with Sanofi Pasteur and Bavarian Nordic dominating the landscape. Long-term growth is supported by climate change expanding disease vectors and aging vaccine stocks requiring replacement. Innovation is gaining momentum, with next-generation recombinant vaccines in pipelines aiming to address safety concerns and improve single-dose efficacy. Demand-supply balance is generally stable, but sporadic shortages during epidemic surges highlight production constraints. Key risks include regulatory hurdles for new entrants, adverse event reporting impacting vaccine confidence, and geopolitical disruptions in low-resource regions. Strategic investments in scalable manufacturing and partnerships with global health organizations are critical for sustained market penetration.

11 items

1. Executive Summary

2. Yellow Fever Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Yellow Fever Vaccines Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Yellow Fever Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Routine Immunization

6.1.2. Travelers

6.1.3. Other

6.2. Global Yellow Fever Vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Institonal Contributions

6.2.2. Private Purchase

6.2.3. Others

6.3. Global Yellow Fever Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Yellow Fever Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Yellow Fever Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Yellow Fever Vaccines Market Competition by Key Manufacturers

8.1. Global Yellow Fever Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Yellow Fever Vaccines: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sanofi Pasteur

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bio-Manguinhos

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. FSUE Chumakov

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Institut Pasteur de Dakar

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Yellow Fever Vaccines Market

Figure 4: Global Yellow Fever Vaccines Market: Drivers

Figure 5: Global Yellow Fever Vaccines Market: Challenges

Figure 6: Global Yellow Fever Vaccines Market: Trends

Figure 7: Global Yellow Fever Vaccines Market: Opportunity

Figure 8: Global Yellow Fever Vaccines Market: Restraint

Figure 9: Global Yellow Fever Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Yellow Fever Vaccines Market Value (USD Million) By Region

Figure 15: Global Yellow Fever Vaccines Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Yellow Fever Vaccines Market Value (USD Million) By Region

Figure 23: Global Yellow Fever Vaccines Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Yellow Fever Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Yellow Fever Vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Yellow Fever Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Yellow Fever Vaccines Market Value (USD Million) By Region

Table 10: Global Yellow Fever Vaccines Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Yellow Fever Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Yellow Fever Vaccines Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Yellow Fever Vaccines Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sanofi Pasteur Basic Information And Sales Area

Table 31: Sanofi Pasteur. Products Portfolio

Table 32: Bio-Manguinhos Basic Information And Sales Area

Table 33: Bio-Manguinhos. Products Portfolio

Table 34: FSUE Chumakov Basic Information And Sales Area

Table 35: FSUE Chumakov. Products Portfolio

Table 36: Institut Pasteur de Dakar Basic Information And Sales Area

Table 37: Institut Pasteur de Dakar. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Yellow Fever Vaccines Market Value (USD Million) By Region

Table 43: Global Yellow Fever Vaccines Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Yellow Fever Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	744.75 million
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi Pasteur; Bio-Manguinhos; FSUE Chumakov; Institut Pasteur de Dakar
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Yellow Fever Vaccines Segmentation Breakdown8 items

Application

Routine Immunization

Travelers

Other

Types

Institonal Contributions

Private Purchase

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: Policy mandates for international travelers, high vaccine affordability, and mature healthcare infrastructure.

Europe: Regulatory harmonization, high vaccination compliance, and cross-border collaboration in disease prevention.

Asia Pacific: Urbanization, population growth, and government-led initiatives to reduce disease burden.

Latin America: Endemic disease prevalence, regional health alliances, and improved access to subsidized vaccines.

Middle East & Africa: Increasing global health funding, awareness campaigns, and partnerships with WHO and GAVI.

Competitive Landscape

Sanofi Pasteur: Innovation pipeline for next-gen vaccines

Bio-Manguinhos: Regional expansion via public-private partnerships

FSUE Chumakov: Cost advantages through local manufacturing in Russia

Institut Pasteur de Dakar: Focus on African market penetration

Teva Pharmaceutical Industries: OEM tie-ups for bulk vaccine supply

Bharat Biotech: Vertical integration to reduce dependency on raw material imports

Key Yellow Fever Vaccines Companies4 items

Sanofi Pasteur

Bio-Manguinhos

FSUE Chumakov

Institut Pasteur de Dakar

Market Ecosystem

Raw material suppliers — provide critical components such as chick embryos, cell cultures, and adjuvants for vaccine production

Vaccine manufacturers — develop and produce yellow fever vaccines using established strains like 17D

Technology providers — supply bioreactors, purification systems, and fill/finish equipment for vaccine production

Regulatory authorities — enforce compliance with GMP standards and oversee vaccine licensure and post-market safety monitoring

Distributors/logistics partners — manage cold chain storage, transportation, and last-mile delivery to healthcare facilities

Healthcare providers — administer vaccines to at-risk populations and report adverse events to health authorities

NGOs and public health agencies — coordinate mass vaccination campaigns and fund access in low-income endemic regions

Recent Industry Insights

Analyst Overview

Table of Contents